Eli Lilly's oral GLP-1 Foundayo approved in record time; retatrutide hits 28.7% weight loss in Phase 3; semaglutide linked to rare skin condition.
10 stories · Covering industry, clinical-trials, research, regulatory
The Foundayo (orforglipron) FDA approval wave continues to dominate headlines, with Scientific American, NBC News, BioSpace, and NPR affiliates all publishing deep-dive coverage on how Eli Lilly's oral GLP-1 pill stacks up against Wegovy and reshapes the obesity drug market. Meanwhile, Retatrutide made a splash with TRIUMPH-4 Phase 3 data showing 28.7% weight loss and significant knee pain reduction in osteoarthritis patients. On the industry side, Hims & Hers stock retreated after initial peptide-regulation optimism faded, and Endpoints News explored how digital health companies like Noom are betting big on the peptide trend.
Top Stories:
In-depth comparison of Foundayo against existing GLP-1 drugs, noting 27 lbs average weight loss over 72 weeks at the highest dose. Experts hope more oral options will drive down costs and offer patients greater flexibility versus injectable regimens.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
A new study identified a potential link between semaglutide use and a rare dermatological pain syndrome. Researchers also referenced Phase 2 retatrutide data as part of broader incretin safety analysis.
Foundayo became the first new molecular entity cleared under the Commissioner's National Priority Voucher Program, with review completed 294 days before the PDUFA date. Commercial pricing set at $25/month insured and $149/month self-pay at the lowest dose.
BioSpace reports Lilly launched Foundayo with $1.5 billion in pre-built inventory. Available via LillyDirect with prescriptions accepted immediately and shipping beginning April 6.
NBC News covers Foundayo's approval with self-pay pricing from $149-$349/month across six dose tiers. Medicare coverage for some patients could begin as early as summer 2026 with copays as low as $50/month.
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.
Digital health companies are betting on peptides as the next big wellness category. They're banking on HHS Secretary RFK Jr. getting the FDA to lift restrictions on certain peptides.
New data shows the first oral CGRP antagonist ubrogepant demonstrates better efficacy when administered during mild pain rather than waiting for moderate-to-severe migraine pain.
Analyst deep-dive into Lilly's position as healthcare's most valuable company, with ~60% U.S. incretin market share driven by tirzepatide and a retatrutide pipeline showing ~30% weight loss potential.